Claims for Patent: 6,500,829

Summary for Patent: 6,500,829

Title:	Substantially pure diastereoisomers of tetrahydrofolate derivatives
Abstract:	The present invention related to the preparation of substantially pure diastereoisomers of derivatives of tetrahydrofolate and the use of such diastereoisomers. More particularly the present invention provides a process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester. The process comprises the steps of: attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S diastereoisomers of tetrahydrofolic acid, separating the new diastereoisomers, recovering the desired new diastereoisomer (6R or 6S) corresponding to the desired (6R or 6S) diastereoisomer, and converting the substantially pure new diastereoisomer recovered into the corresponding diastereoisomer.
Inventor(s):	Wood; Hamish Christopher Swan (Glasgow, GB), Suckling; Colin James (Glasgow, GB), Rees; Lilias G. (Glasgow, GB)
Assignee:	University of Strathclyde (Glasgow, GB)
Application Number:	08/426,458
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,500,829
Patent Claims:	1. A pharmaceutical composition for therapeutic use which consists essentially of a therapeutically effective amount sufficient for the treatment of human beings for methotrexate rescue or folate deficiency, of a pharmaceutically acceptable compound which is a (6S) diastereoisomer selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S) leucovorin; wherein the compound consists of a mixture of (6S) and (6R) diastereoisomers and consists of at least 92% by weight of the (6S) diastereoisomer, the balance of said compound consisting of the (6R) diastereoisomer; in combination with a pharmaceutically acceptable carrier. 2. The pharmaceutical composition according to claim 1 which consists of greater than 95% by weight of the (6S) diastereoisomer. 3. The pharmaceutical composition according to claim 1 which consists essentially of about 92% by weight of the (6S) diastereoisomer. 4. The pharmaceutical composition according to claim 1 which consists essentially of 92% to 95% by weight of the (6S) diastereoisomer. 5. A pharmaceutical composition for therapeutic use for the treatment of human beings comprising: a pharmaceutically acceptable composition which is a (6S) diastereoisomer selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S) leucovorin, wherein the composition consists of a mixture of (6S) and (6R) diastereoisomers and consists of at least about 92% by weight of the (6S) diastereoisomer, the balance of said composition consisting of the (6R) diastereoisomer; and a pharmaceutically acceptable carrier; and said composition being of a quantity at least sufficient to provide multiple doses of said mixture of (6S) and (6R) diastereoisomers in an amount of 2000 mg per dose. 6. The pharmaceutical composition for therapeutic use for the treatment of human beings as defined in claim 5 wherein said mixture of (6S) and (6R) diastereoisomers is present in said composition in an amount of at least about 10 grams. 7. The pharmaceutical composition for therapeutic use for the treatment of human beings as defined in claim 5 wherein said mixture of (6S) and (6R) diastereoisomers consists of at least about 95% by weight of the (6S) diastereoisomer, the balance of said composition consisting of the (6R) diastereoisomer. 8. The pharmaceutical composition for therapeutic use for the treatment of human beings as defined in claim 5 wherein said composition is present in a form selected from the group consisting of injectable solutions; powders for injection which can be reconstituted shortly before use by addition of water for injection; and tablets. 9. The pharmaceutical composition for therapeutic use for the treatment of human beings as defined in claim 5 wherein said composition is produced as a result of separation by differential solubility in a polar solvent of a (6S) diastereoisomer from an initial mixture containing equal amounts of (6S) and (6R) diastereoisomers. 10. A pharmaceutical composition for preparing medicaments for therapeutic use in the treatment of human beings consisting of a mixture of: a (6S) diastereoisbmer selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S) leucovorin and the (6R) diastereoisomer thereof; wherein said mixture of (6S) and (6R) diastereoisomers consists of at least about 92% by weight of the (6S) diastereoisomer, the balance of said composition consisting of the (6R) diastereoisomer; and said mixture of (6S) and (6R) diastereoisomers being present in said pharmaceutical composition in an aggregate quantity at least sufficient to provide multiple doses of said mixture in an amount of 2000 mg per dose. 11. The pharmaceutical composition for preparing medicaments for therapeutic use in the treatment of human beings as defined in claim 10 wherein said mixture of (6S) and (6R) diastereoisomers is present in said composition in an amount of at least about 10 grams. 12. The pharmaceutical composition for preparing medicaments for therapeutic use in the treatment of human beings as defined in claim 10 wherein said mixture of (6S) and (6R) diastereoisomers consists of at least about 95% by weight of the (6S) diastereoisomer, the balance of said composition consisting of the (6R) diastereoisomer. 13. The pharmaceutical composition for therapeutic use for the treatment of human beings prepared from the composition of claim 12 in a form selected from the group consisting of injectable solutions; powders for injection which can be reconstituted shortly before use by addition of water for injection; and tablets. 14. The pharmaceutical composition for therapeutic use for the treatment of human beings as defined in claim 10 wherein said composition is produced as a result of separation by differential solubility in a polar solvent of a (6S) diastereoisomer from an initial mixture containing equal amounts of (6S) and (6R) diastereoisomers.